De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Standard BioTools Toekomstige groei

Future criteriumcontroles 1/6

Standard BioTools zal naar verwachting groeien in winst en omzet met respectievelijk 55.5% en 19.2% per jaar. De winst per aandeel zal naar verwachting groeien met 68.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -15.8% zijn.

Belangrijke informatie

55.5%

Groei van de winst

68.5%

Groei van de winst per aandeel

Life Sciences winstgroei	17.5%
Inkomstengroei	19.2%
Toekomstig rendement op eigen vermogen	-15.8%
Dekking van analisten	Low
Laatst bijgewerkt	01 Aug 2024

Recente toekomstige groei-updates

Recent updates

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Sep 14

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

Aug 05

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Jul 26

Winst- en omzetgroeiprognoses

NasdaqGS:LAB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	242	-36	-5	0	2
12/31/2025	198	-89	-71	-67	3
12/31/2024	172	-163	-149	-142	3
6/30/2024	136	-165	-131	-127	N/A
3/31/2024	127	-136	-100	-97	N/A
12/31/2023	106	-75	-46	-43	N/A
9/30/2023	105	-76	-52	-48	N/A
6/30/2023	105	-84	-65	-62	N/A
3/31/2023	97	-131	-86	-82	N/A
12/31/2022	98	-190	-93	-89	N/A
9/30/2022	109	-179	-81	-77	N/A
6/30/2022	112	-163	-66	-62	N/A
3/31/2022	124	-117	-54	-47	N/A
12/31/2021	131	-59	-57	-44	N/A
9/30/2021	137	-68	-64	-41	N/A
6/30/2021	148	-60	-58	-36	N/A
3/31/2021	143	-56	-43	-24	N/A
12/31/2020	138	-53	-28	-15	N/A
9/30/2020	126	-48	-20	-17	N/A
6/30/2020	113	-55	-21	-17	N/A
3/31/2020	115	-55	-23	-19	N/A
12/31/2019	117	-65	-38	-35	N/A
9/30/2019	117	-67	-32	-30	N/A
6/30/2019	120	-69	-31	-30	N/A
3/31/2019	118	-71	-30	-29	N/A
12/31/2018	113	-59	-26	-25	N/A
9/30/2018	108	-55	-24	-24	N/A
6/30/2018	104	-56	-29	-28	N/A
3/31/2018	102	-57	N/A	-32	N/A
12/31/2017	102	-61	N/A	-24	N/A
9/30/2017	99	-68	N/A	-35	N/A
6/30/2017	97	-72	N/A	-41	N/A
3/31/2017	101	-73	N/A	-40	N/A
12/31/2016	104	-76	N/A	-39	N/A
9/30/2016	110	-71	N/A	-33	N/A
6/30/2016	117	-61	N/A	-32	N/A
3/31/2016	117	-57	N/A	-33	N/A
12/31/2015	115	-53	N/A	-35	N/A
9/30/2015	117	-51	N/A	-34	N/A
6/30/2015	118	-56	N/A	-30	N/A
3/31/2015	117	-53	N/A	-22	N/A
12/31/2014	116	-53	N/A	-23	N/A
9/30/2014	104	-47	N/A	-16	N/A
6/30/2014	92	-37	N/A	-8	N/A
3/31/2014	82	-28	N/A	-11	N/A
12/31/2013	71	-17	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat LAB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat LAB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat LAB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van LAB ( 19.2% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van LAB ( 19.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat LAB binnen 3 jaar verliesgevend zal zijn.

Standard BioTools Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 15%

No longer forecast to breakeven

Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024

Forecast to breakeven in 2026

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Consensus EPS estimates upgraded to US$0.43 loss

Recent updates

Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher

Consensus revenue estimates decrease by 15%

Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts

No longer forecast to breakeven

Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Standard BioTools Inc. Announces Chief Financial Officer Changes

Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%

Forecast to breakeven in 2026

High number of new and inexperienced directors

Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024

Standard BioTools Inc., Annual General Meeting, Jun 27, 2024

Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024

Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024

Standard BioTools Inc. Announces Operational Restructuring Plan

Now 21% undervalued

Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging

Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?

Consensus EPS estimates upgraded to US$0.43 loss

Chief Strategy Officer notifies of intention to sell stock

Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)

Forecast to breakeven in 2026

Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024

New major risk - Financial position

Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable

Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024

Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?

New major risk - Revenue and earnings growth

Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Standard BioTools (NASDAQ:LAB) A Risky Investment?

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023

High number of new directors

Senior VP & CFO recently bought US$194k worth of stock

Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System

Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer

First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022)

Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors

Chief Financial Officer exercised options and sold US$58k worth of stock

Standard BioTools Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021)

Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023

Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer

Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares.

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021)

Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022

Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform

Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021)

Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022

Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022

Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary

Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations

Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Standard BioTools Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$6.00

Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022

Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging

Independent Director exercised options to buy US$80k worth of stock.

Fluidigm Corporation Announces Board Changes

Fluidigm Corporation Announces Management Changes

Price target decreased to US$6.00

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Fluidigm Corporation: Investment Opportunity